Payment overview · 2025
General Payments
$502.84
29 reported records · 7 companies
Healthcare provider profile · identity verified
Robin Louise Goodwin, C-FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · KINGWOOD, WV · NPI 1598058836
Verified facts
What the public records show
CMS Open Payments records show Robin Louise Goodwin, C-FNP received $502.84 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 41.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $208.74 | 41.5% | 20 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $162.74 | 32.4% | 2 | 2025 |
| MILLICENT US INC | Unresolved — no canonical attribution shown | $63.24 | 12.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.65 | 3.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.51 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.07 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.89 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $502.84 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $162.74 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $120.70 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.04 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.39 | 7 | 2025 |
Source payment records
|
|||||
| FEMLYV Normalized: femlyv |
Drug | MILLICENT US INC | $63.24 | 3 | 2025 |
Source payment records
|
|||||
| INTRAROSA Normalized: intrarosa |
Drug | MILLICENT US INC | $63.24 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 222 | 53 |
| Lisinopril | Lisinopril | 213 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 147 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 36 |
| Metformin Hcl | Metformin Hcl | 123 | 40 |
| Omeprazole | Omeprazole | 120 | 34 |
| Prednisone | Prednisone | 118 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 30 |
| Furosemide | Furosemide | 103 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 97 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 76 |
| Gabapentin | Gabapentin | 74 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 19 |
| Montelukast Sodium | Montelukast Sodium | 72 | 17 |
| Simvastatin | Simvastatin | 69 | 23 |
| Ozempic | Semaglutide | 60 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 59 | 16 |
| Meloxicam | Meloxicam | 58 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 44 |
| Fluconazole | Fluconazole | 54 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 13 |
| Sertraline Hcl | Sertraline Hcl | 53 | 19 |
| Famotidine | Famotidine | 52 | 14 |
| Trazodone Hcl | Trazodone Hcl | 52 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 48 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | 13 |
| Amoxicillin | Amoxicillin | 46 | 43 |
| Eliquis | Apixaban | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 22 |
| Losartan Potassium | Losartan Potassium | 45 | 16 |
| Ibuprofen | Ibuprofen | 44 | 15 |
| Glipizide | Glipizide | 42 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | 14 |
| Spironolactone | Spironolactone | 39 | 13 |
| Buspirone Hcl | Buspirone Hcl | 38 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 13 |
| Topiramate | Topiramate | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Cefdinir | Cefdinir | 26 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | 11 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Ofloxacin | Ofloxacin | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nystatin | Nystatin | 18 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Novolog | Insulin Aspart | 12 | suppressed |
| Erythromycin | Erythromycin Base | 11 | 11 |
| Lamotrigine | Lamotrigine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $502.84 · 29 records | ABBVIE INC. | AIRSUPRA, FEMLYV, FREESTYLE LIBRE 3, INTRAROSA, JOURNAVX, PAXLOVID, QULIPTA, UBRELVY, VRAYLAR, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error